Transformation to small-cell lung cancer following treatment with EGFR tyrosine kinase inhibitors in a patient with lung adenocarcinoma

Lung Cancer

Volumn 82, Issue 2, 2013, Pages 370-372

  Watanabe, Satoshi ^a   Sone, Takashi ^a   Matsui, Tomoharu ^a   Yamamura, Kenta ^a   Tani, Mayuko ^a   Okazaki, Akihito ^a   Kurokawa, Koji ^a   Tambo, Yuichi ^a   Takato, Hazuki ^a   Ohkura, Noriyuki ^a   Waseda, Yuko ^a   Katayama, Nobuyuki ^a   Kasahara, Kazuo ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

Author keywords

Adenocarcinoma; EGFR tyrosine kinase inhibitors; NSE; ProGRP; Resistance; Small cell lung cancer; Transformation

Indexed keywords

CARBOPLATIN; CISPLATIN; ERLOTINIB; ETOPOSIDE; PEMETREXED;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HISTOPATHOLOGY; HUMAN; LUNG ADENOCARCINOMA; LUNG BIOPSY; LUNG NODULE; LUNG SMALL CELL CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SPINE TUMOR; TREATMENT RESPONSE;

ADENOCARCINOMA; EGFR TYROSINE KINASE INHIBITORS; NSE; PROGRP; RESISTANCE; SMALL CELL LUNG CANCER; TRANSFORMATION;

ADENOCARCINOMA; BIOLOGICAL MARKERS; BIOPSY; FEMALE; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SMALL CELL LUNG CARCINOMA; TREATMENT OUTCOME;

EID: 84887020905     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.06.003     Document Type: Article

References (11)

1. Mitsudomi T., Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 2007, 98:1817-1824.
2. Kobayashi S., Boggon T.J., Dayaram T., Jänne P.A., Kocher O., Meyerson M., et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005, 352(8):786-792.
3. Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316(5827):1039-1043.
4. Yano S., Wang W., Li Q., Matsumoto K., Sakurama H., Nakamura T., et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res 2008, 68(22):9479-9487.
5. Yamamoto C., Basaki Y., Kawahara A., Nakashima K., Kage M., Izumi H., et al. Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations. Cancer Res 2010, 70(21):8715-8725.
6. Suda K., Tomizawa K., Fujii M., Murakami H., Osada H., Maehara Y., et al. Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib. J Thorac Oncol 2011, 6(7):1152-1161.
7. Zakowski M.F., Ladanyi M., Kris M.G., Memorial Sloan-Kettering Cancer Center Lung Cancer OncoGenome Group EGFR mutations in small cell lung cancers in patients who have never smoked. N Engl J Med 2006, 355(2):213-215.
8. Morinaga R., Okamoto I., Furuta K., Kawano Y., Sekijima M., Dote K., et al. Sequential occurrence of non-small cell and small cell lung cancer with the same EGFR mutation. Lung Cancer 2007, 58(3):411-413.
9. Tatematsu A., Shimizu J., Murakami Y., Horio Y., Nakamura S., Hida T., et al. Epidermal growth factor receptor mutations in small cell lung cancer. Clin Cancer Res 2008, 14(19):6092-6096.
10. Sequist L.V., Waltman B.A., Dias-Santagata D., Digumarthy S., Turke A.B., Fidias P., et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011, 3(75):75ra26.
11. Yu H.A., Arcila M.E., Rekhtman N., Sima C.S., Zakowski M.F., Pao W., et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI Therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 2013, 19(8):2240-2247.